Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's MOFCOM Promises Increased Scrutiny Over M&A In 2012

This article was originally published in PharmAsia News

Executive Summary

China Ministry of Commerce announcement of increased M&A scrutiny, sends companies scrambling to submit papers in fear of bureaucratic delays.

You may also be interested in...



More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity

HONG KONG - Much awaited regulations on how China will review inbound mergers and acquisitions in light of national security and competition suggest long waits for pending and future deals and new barriers to entry, say some business groups

What Does China's Price Manipulation Ruling On Unilever Mean For Global Pharma? (Part 2 of 2)

[Editor's note: This is part two of a two-part feature; part one covered the background of China's National Development and Reform Commission charge against consumer goods company Unilever and what multinational companies operating in China should take away from the incident. This second part looks at the larger impact of China's inflation on pharma companies.]

Novartis Tagged With Anti-monopoly Conditions In China For Alcon Acquisition

HONG KONG - China's growing assertiveness in commercial matters is becoming evident in its influence on merger and acquisitions matters and its willingness to impose conditions under its two-year-old anti-monopoly law

Related Content

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel